Liver Fibrosis Treatment Market Rapid Growth By Leading Players Gilead Sciences, Inc., Pfizer Inc, Merck & Co., Inc., Bristol-Myers Squibb, Novartis AG.

Increasing number of clinical trials by key players focused on development of an efficient treatment option for liver fibrosis is expected to drive the growth of the liver fibrosis treatment market in near future. In October 2010, FibroGen, Inc. initiated phase II clinical study of FG-3019: a human monoclonal antibody against the Connective Tissue Growth Factor (CTGF) to compare the efficacy in reversing the effects of liver fibrosis caused by chronic infection with hepatitis B virus (HBV).

In February 2018, Intercept Pharmaceuticals, Inc. initiated phase III trial of REVERSE trial (Randomized Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis). This randomized phase III study will evaluate the efficacy and safety of obeticholic acid in NASH patients with a biopsy-confirmed diagnosis of cirrhosis.

Download PDF Brochure of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2320

Furthermore, growing research collaboration among the key players to develop novel treatment regime combined with regulatory approval of underline drugs for treatment of liver fibrosis is expected to drive the market growth in near future.

For instance, in April 2017, Bristol-Myers Squibb Company and Nordic Bioscience signed a collaboration agreement for development of biomarker technology to potentially diagnose and monitor fibrosis disease including Non-alcoholic steatohepatitis (NASH). This collaboration will help patients to efficiently diagnose and monitor fibrosis disease.
In February 2018, the U.S. Food and Drug Administration (FDA) approved Vertex Pharmaceuticals’ SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people age 12 and older with certain mutations.

Competitive Analysis

Some of the major players operating in the global liver fibrosis treatment market include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited.

Request For Customization Of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2320

Detailed Segmentation:

Global Liver Fibrosis Treatment Market, By Treatment Type:
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
Hepatotropic Drug
Others

Global Liver Fibrosis Treatment Market, By Condition:
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis

Global Liver Fibrosis Treatment Market, By End User:
Hospitals
Specialty Clinics
Retail Pharmacy

Global Liver Fibrosis Treatment Market, By Geography:
North America
By Country:
U.S.
Canada

By Treatment Type:
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
Hepatotropic Drug

By Condition:
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis

By End User:
Hospitals
Specialty Clinics
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.